Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)

NCT04362930 | Completed

• 1 other identifier: APHP200525
• Study Type: observational
• Target: 730
• Locations: 1 country
• Sites: 1

Brief Summary

Covid-19 pandemic now affects more than two million people worldwide. The neurotropism of the virus is assumed by its frequent association with neurological symptoms (anosmia, ageusia, headaches) but the extent of the central or peripheral nervous system involvement and the associated symptomatology remain poorly known for now. The main objective of this study is to describe the neurological and psychiatric manifestations occurring in the context of Covid-19 infection in patients hospitalized or followed-up in the APHP.SU hospital group. A better understanding of the neuropsychiatric impairment related to Covid-19 would improve the management of these patients in the acute phase, and knowledge of subsequent complications would allow adapting their rehabilitation and follow-up. The precise phenomenological description of these manifestations and the imaging, biology and neuropathology data will be compiled from the data collected by the physicians in charge of these patients as part of their inpatient or outpatient care. This study will also allow collecting unusual clinical manifestations from patients followed for neurological or psychiatric pathology in hospital departments and presenting a Covid-19 infection, in order to optimize the reorganization of their management, follow-up and rehabilitation in the epidemic context.

Conditions

Neurologic Manifestations; Psychiatric Disorders; COVID-19

Keywords

COVID-19; ENCEPHALOPATHY; ENCEPHALITIS; STROKE; CONFUSION; DELIRIUM; DEPRESSION; POST TRAUMATIC STRESS DISORDER

Outcome Measures

Primary Outcomes (1)

• Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19

  Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19

  12 months

Secondary Outcomes (1)

• Progression of pre-existing neurological or psychiatric pathologies

  12 months

Study Arms (2)

Neurological and psychiatric impact of COVID-19

Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection

Impact of Covid-19 in patients with neurological pathology

patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Covid-19 infection showing neurological or psychiatric symptoms and patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection

You may qualify if:

• Age of 18 years or over
• Patient followed for a neurological or psychiatric pathology OR Patient consulting and presenting a neurological or psychiatric impairment AND
• Presenting a COVID-19 infection defined by at least one of the following three criteria:
• Biological diagnosis by any method for direct detection of the virus (Covid-19 positive PCR) or recent infection (serology)
• Typical chest imaging (CT scan or X-ray) in an epidemic area
• Clinical-biological data leading to a strong suspicion of current or past Covid-19 infection
• Non-opposition of the participant, relative or guardian to the research

You may not qualify if:

• Patient under safety measure

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Hôpital Pitié Salpétrière

Paris, 75013, France

Location

Related Publications (1)

• Pitron V, Cantenys W, Herbelin A, Bottemanne H, Dzierzynski N, Caumes E, Mathian A, Amoura Z, Allenbach Y, Cacoub P, Parrot A, Rotge JY, Fossati P. Factors Associated With Posttraumatic Stress Symptoms 3 and 6 Months After Hospitalization for COVID-19: A Longitudinal Multicenter Study. J Clin Psychiatry. 2022 Dec 7;84(1):21m14277. doi: 10.4088/JCP.21m14277.

  PMID: 36479951 DERIVED

Related Links

• CoCo-Neurosciences project is described on the Paris Brain Institute website

MeSH Terms

Conditions

Neurologic Manifestations; Mental Disorders; COVID-19; Brain Diseases; Encephalitis; Stroke; Confusion; Delirium; Depression; Stress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Central Nervous System Diseases; Neuroinflammatory Diseases; Cerebrovascular Disorders; Vascular Diseases; Cardiovascular Diseases; Neurobehavioral Manifestations; Neurocognitive Disorders; Behavioral Symptoms; Behavior; Stress Disorders, Traumatic; Trauma and Stressor Related Disorders

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 24, 2020
• First Posted: April 27, 2020
• Study Start: April 27, 2020
• Primary Completion: June 30, 2022
• Study Completion: June 30, 2022
• Last Updated: February 5, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)